BioSight
Companies
ASSEMBLY BIOSCIENCES, INC. logo

ASMB

NASDAQSOUTH SAN FRANCISCO, CA
ASSEMBLY BIOSCIENCES, INC.

Assembly Biosciences is a clinical-stage biotechnology company developing antivirals targeting serious viral diseases, with a portfolio including two long-acting helicase-primase inhibitors ABI-1179 and ABI-5366 for recurrent genital herpes (which Gilead licensed in December 2025), the hepatitis delta virus entry inhibitor ABI-6250 advancing toward Phase 2, the hepatitis B virus capsid assembly modulator ABI-4334 in partnering discussions, and the oral broad-spectrum non-nucleoside polymerase inhibitor ABI-7272 for transplant-associated herpesviruses in regulatory filing-enabling studies. All lead programs have reported positive Phase 1 clinical data in 2025.

Price history not yet available for ASMB.

Pipeline

No pipeline data on record yet.

Catalyst Calendar

No catalyst events on record for yet. Check back after the next daily ingest.

Disclaimer·BioSight aggregates publicly available data (SEC EDGAR, ClinicalTrials.gov, FDA, company press releases) and is provided as is for informational purposes only. Nothing here is investment, financial, legal, tax, or medical advice, or an offer to buy or sell any security. We make no warranty as to accuracy, completeness, or timeliness; dates and filings may contain errors or be superseded without notice; past events do not predict future outcomes. To the maximum extent permitted by law, BioSight, its operators, contributors, and affiliates disclaim all liability for any loss or damage arising from use of or reliance on this site. You are solely responsible for your own investment decisions — consult a licensed professional before acting on any information.

Unlock 12-month calendar